BR112013029256A8 - combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 - Google Patents
combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2Info
- Publication number
- BR112013029256A8 BR112013029256A8 BR112013029256A BR112013029256A BR112013029256A8 BR 112013029256 A8 BR112013029256 A8 BR 112013029256A8 BR 112013029256 A BR112013029256 A BR 112013029256A BR 112013029256 A BR112013029256 A BR 112013029256A BR 112013029256 A8 BR112013029256 A8 BR 112013029256A8
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes
- type
- pharmaceutical combination
- treating patients
- patients
- Prior art date
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052 | 2011-05-13 | ||
| PCT/EP2012/058779 WO2012156312A1 (en) | 2011-05-13 | 2012-05-11 | Pharmaceutical combination for use in the treatment of diabetes type 2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112013029256A2 BR112013029256A2 (pt) | 2016-11-29 |
| BR112013029256A8 true BR112013029256A8 (pt) | 2018-01-16 |
Family
ID=46052773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013029256A BR112013029256A8 (pt) | 2011-05-13 | 2012-05-11 | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130040878A1 (https=) |
| EP (1) | EP2709652A1 (https=) |
| JP (1) | JP6005140B2 (https=) |
| KR (1) | KR20140041553A (https=) |
| CN (2) | CN109045283A (https=) |
| AR (1) | AR086356A1 (https=) |
| AU (1) | AU2012257780B2 (https=) |
| BR (1) | BR112013029256A8 (https=) |
| CA (1) | CA2835336A1 (https=) |
| MX (1) | MX356728B (https=) |
| RU (2) | RU2017129878A (https=) |
| WO (1) | WO2012156312A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PL2611458T3 (pl) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| AU2014207748B2 (en) * | 2013-01-17 | 2018-10-11 | Vtv Therapeutics Llc | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
| MX2016008978A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol. |
| BR112016015851A2 (pt) | 2014-01-09 | 2017-08-08 | Sanofi Sa | Formulações farmacêuticas estabilizadas de insulina aspart |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US12459954B2 (en) | 2020-04-01 | 2025-11-04 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of GLP-1 receptor agonist and preparation method therefor |
| JP2023528726A (ja) | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
| PL2324853T3 (pl) * | 2009-11-13 | 2016-01-29 | Sanofi Aventis Deutschland | Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2 |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en not_active Ceased
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko not_active Ceased
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013013198A (es) | 2014-02-20 |
| CN103648519A (zh) | 2014-03-19 |
| BR112013029256A2 (pt) | 2016-11-29 |
| US20130040878A1 (en) | 2013-02-14 |
| WO2012156312A1 (en) | 2012-11-22 |
| EP2709652A1 (en) | 2014-03-26 |
| MX356728B (es) | 2018-06-12 |
| KR20140041553A (ko) | 2014-04-04 |
| CA2835336A1 (en) | 2012-11-22 |
| CN109045283A (zh) | 2018-12-21 |
| JP6005140B2 (ja) | 2016-10-12 |
| RU2017129878A (ru) | 2019-02-05 |
| AU2012257780B2 (en) | 2017-06-01 |
| RU2013155480A (ru) | 2015-06-20 |
| AR086356A1 (es) | 2013-12-04 |
| JP2014518860A (ja) | 2014-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| BR112014004726A2 (pt) | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 | |
| BR112014005025A2 (pt) | composição farmacêutica para uso no tratamento de uma doença neurodegenerativa | |
| BR112013029269A8 (pt) | combinação farmacêutica para uso na indução de perda de peso em pacientes com diabetes tipo 2 e/ou para prevenir o ganho de peso em pacientes com diabetes tipo 2 | |
| BR112014032938A2 (pt) | uso de peptídeos de glp-1 de longa ação | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| BR112015026325A2 (pt) | dosagem oral de compostos glp-1 | |
| BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
| BR112014032990A2 (pt) | seringa | |
| BR112014011594A2 (pt) | anticorpos anti-il-36r | |
| BR112013031268A8 (pt) | polipeptídeos | |
| BR112013020809A2 (pt) | composição para uso no tratamento ou prevenção de disturbio ou doença relacionada a uma mucosa | |
| IL232251B (en) | Pharmaceutical combination for use in the treatment of type 2 diabetes patients | |
| BR112014030406A2 (pt) | combinação de canabidiol fitocanabinoide com hipotermia terapêutica | |
| BR112012017488A2 (pt) | "dispositivo" | |
| MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
| BR112013029062A2 (pt) | lixisenatida e metformina para o tratamento de diabetes tipo 2 | |
| CL2008000198A1 (es) | Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis. | |
| UY34859A (es) | Análogos peptídicos de la exendina 4. | |
| BR112014003704A2 (pt) | moduladores ror gama | |
| MX2015013939A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. | |
| BR112014011481A2 (pt) | hidrolisado de colágeno e seu uso | |
| CO7160080A2 (es) | Composiciones lipídicas de racecadotrillo | |
| CR20170376A (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |